Friday, 20 Sep 2019

You are here

Monocyte Patrolling Contributes to Lupus Glomerulonephritis

Systemic lupus erythematosus (SLE) is an autoimmune disease with a propensity to develop glomerulonephritis (47-70%) or end-stage kidney disease despite therapy.

Hallmarks of the disease are the appearance of immune complexes (IC) containing autoreactive Abs and TLR-activating nucleic acids, whose deposition in kidney glomeruli is suspected to promote tissue injury and glomerulonephritis (GN).

The pathogenesis of lupus GN was investigated using 3 different mouse models of SLE and SLE patients all of whom demonstrated glomerular accumulation of patrolling monocytes (PMos), a cell type with an emerging key function in vascular inflammation.

Lupus nephritis is considered an immune complex–mediated (IC-mediated) form of GN. Although the relevance of ICs in lupus nephritis is debated, IC deposition cand lead to complement-mediated cytotoxicity and end-organ damage.

ICs may also contribute to GN by activating Toll-like receptors (TLR), including TLR7, TLR8, and TLR9, on B cells, further contributing the tissue damage and inflammation. It is possible that the therapeutic efficacy of antimalarials are mediated by the prevention of TLR activation.

A potential B cell–independent mechanism for lupus GN is supported by more than 50 genetic SLE susceptibility loci with functions outside the adaptive immune system. One such susceptibility locus for SLE and lupus GN TNIP1 (TNFAIP3-interacting protein 1; also referred to as ABIN1, A20-binding inhibitor of NF-κB activation 1).  ABIN1 is a negative regulator of the TNFR, TLR, and IL-17R pathways, and, ABIN1-deficient mice develop a systemic lupus-like disease that includes major characteristics of human SLE, including autoreactive Abs and severe GN.

Studies reported in the Journal of Clinical Investigation have shown that monocyte-specific deletion of ABIN1, promoted kidney disease, whereas selective elimination of patrolling monocytes provided protection against GN.

Patrolling monocytes (PMos) are one of the two monocytes found in the peripheral blood (PB), PMos numbers are increased in the PB and kidney glomeruli of lupus.  Investigators have shown that PMos are capable of mediating tissue injury in lupus-nephritis based on studies done to characterize GN in ABIN1-deficient mice and 2 additional independent lupus models. 

These data identify TLR-activated PMos as the principal component of an intravascular process that contributes to glomerular inflammation and kidney injury. based on the SLE susceptibility locus TNFAIP3-interacting protein 1 (TNIP1, also known as ABIN1).

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Sensitivity of Temporal Artery Biopsy

Metanalysis shows that temporal artery biopsy (TAB) for the diagnosis of giant cell arteritis (GCA) has a sensitivity of 77%, similar to results seen with temporal artery imaging. These data suggest clinicians may be willing to accept a GCA diagnosis without proof by TAB.

FDA Grants Breakthrough Status for Potential Lupus Nephritis Drug

Obinutuzumab (Gazyva) has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for use in adults with lupus nephritis (LN). The drug made by Genentech, is going forward based on the Phase II NOBILITY study in adult patients with proliferative lupus nephritis (LN). Currently, there are no FDA-approved medicines for lupus nephritis.

Riociguat Fails in Systemic Sclerosis-Associated Digital Ulcers

Riociguat is an oral, selective soluble guanylate cyclase stimulator that has been studied in patients with digital ulcers (DU) due to systemic sclerosis (SSc) but study results show that short term (16 weeks) riociquat therapy does not sufficiently reduce the DU burden in SSc patients.

Nintedanib FDA Approved for Scleroderma Lung Disease

Last Friday, the US Food and Drug Administration approved Ofev (nintedanib) to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. ILD as a complication of SSc may lead to progressive loss of lung function and may be associated with a significant mortality risk. Prior to the approval of Olev, there were no FDA approved drugs for SSc-ILD.

With Autoimmunity, Checkpoint Inhibitors Can Be Used

Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.